Research-based biopharmaceutical company AbbVie Inc. (NYSE:ABBV) Thursday said it has filed a New Drug Submission to Health Canada for the company’s therapy for adults with genotype 1 chronic hepatitis C virus (HCV) infection, including those with cirrhosis. AbbVie Inc. (NYSE:ABBV) net profit margin is 21.80% and weekly performance is 1.93%. On last trading day company shares ended up $53.95. Analysts mean target price for the company is $54.68. AbbVie Inc. (NYSE:ABBV) distance from 50-day simple moving average (SMA50) is 5.55%.
InterMune Inc (NASDAQ:ITMN)’s CEO, Daniel Welch also spoke on the show and appeared positive that the drug will get the required FDA approval, and the company would then be able to introduce the product as early as first quarter of the next year. InterMune Inc. (NASDAQ:ITMN) shares advanced 1.32% in last trading session and ended the day on $39.98. ITMN gross Margin is 87.30% and its return on assets is -44.50%.InterMune Inc. (NASDAQ:ITMN) quarterly performance is 186.39%.
Shares of Aetna (NYSE:AET) have been given a consensus rating of “Buy” by the twenty analysts that are covering the stock, Analyst Ratings Net reports. Four analysts have rated the stock with a hold rating and thirteen have issued a buy rating on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $78.24. Aetna Inc. (NYSE:AET) shares moved up 1.18% in last trading session and was closed at $76.39, while trading in range of $74.49 – $76.49. Aetna Inc. (NYSE:AET) year to date (YTD) performance is 12.07%.
On May 14, 2014 the Board of Directors of WellPoint, Inc. (NYSE;WLP) appointed Joseph R. Swedish to the position of President, in addition to his current Chief Executive Officer position, effective May 14, 2014. WellPoint Inc. (NYSE:WLP) ended the last trading day at $108.82. Company weekly volatility is calculated as 1.53% and price to cash ratio as 15.44.WellPoint Inc. (NYSE:WLP) showed a positive weekly performance of 3.52%.
Humana (NYSE:HUM)‘s stock had its “outperform” rating restated by equities research analysts at Leerink Swann in a research note issued to investors on Friday. They currently have a $140.00 price objective on the stock, up from their previous price objective of $135.00. Leerink Swann’s price objective points to a potential upside of 13.53% from the company’s current price. Humana Inc. (NYSE:HUM) net profit margin is 2.60% and weekly performance is 4.61%. On last trading day company shares ended up $124.49. Analysts mean target price for the company is $119.94. Humana Inc. (NYSE:HUM) distance from 50-day simple moving average (SMA50) is 9.87%.